Price
No data yet.
Social Signal Score
Revenue
$1.40M+3.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Riccardo Canevari
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.80
- Country
- AU
Financials
RADX has only 2 quarterly periods on file — the charts below show the full history available.
Revenue
$1.40M+3.1%Net Income
$-28.58MEBITDA
$-39.91MFree Cash Flow
$0.00EPS (diluted)
$-729.00Shares Outstanding (diluted)
39.4K+0.0%Operating Expenses
$6.41MCash & Debt
$4.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.71M | $-53.94M | $-4.56 |
| 2024 | $3.63M | $-38.34M | $-5.28 |
| 2023 | $299.2K | $-47.95M | $-36.00 |
| 2022 | $292.4K | $-34.61M | $-33.00 |
| 2021 | $8.8K | $-30.34M | $-29.76 |
Valuation
RADXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
…ing potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced positive data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution and dosimetry of RAD 301 in healthy volunt…
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center
View source ↗
Earnings
Fri, Feb 26(in 6 months)
Consensus estimate $-1.05 per share
Typical surprise -20.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 28$-1.67 vs $-1.67beat
- Fri, Feb 27$-2.25 vs $-1.51miss
- Fri, Aug 29$-1.78 vs $-1.58miss
- Fri, Feb 28$-1.91 vs $-1.49miss
Estimates and results for RADX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RADX officers and directors.
No open-market trades in the recent filings. All 31 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.